The past few decades have seen major advances in understanding the pathobiology and clinical management of Hodgkin lymphoma (HL), making it one of the most successfully treated cancers worldwide. At present, more than 90% of patients with early-stage, and up to 80% with advanced-stage disease, are cured with current combined-modality treatment. Nevertheless, some 15% to 30% of all patients resp...

As a reflection of the considerable increase in the number of cancer patients treated with chemotherapy, indications for the use of implanted venous catheters are rapidly growing. However, in some cases, implanted venous catheters induce unwelcome complications. We herein report a rare case of septic pulmonary embolism (SPE) caused by local infection-associated catheter removal during the admin...

20 year old female with no prior medical history presents with diffuse cervical lymphadenopathy. CT and subsequent positron emission tomography-computed tomography (PET/CT) demonstrated diffuse lymphatomous involvement of multiple lymph nodes in the neck, mediastinum, and retroperitoneum. The patient underwent ABVD therapy which resulted in the lymphoma being in remission for 2 years. The patie...

We describe a rare case of Castleman disease associated de novo with Hodgkin lymphoma. The incidence of Castleman disease is rare; only a few studies have described it in de novo association with Hodgkin lymphoma. The patient described here complained of unique evolutionary axillary adenopathy. A positron-emission tomography/computed tomography scan revealed hypermetabolic activity in this area...

Összefoglaló. Az eltűnőepeút-szindróma ritka, rossz prognózisú kórkép. epeutak progresszív destrukciójával, az intrahepaticus eltűnésével jár, epepangáshoz, biliaris cirrhosishoz, végül májelégtelenséghez vezet. A háttérben álló kiváltó okok között infekciók, ischaemia, gyógyszermellékhatások, illetve daganatos megbetegedések szerepelhetnek. malignitások közül a leggyakrabban Hodgkin-lymphomáho...

The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical mode...

Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, such as etoposide did show a long-term risk of developing therapy-related myelodysplasia and acute myelogenous leukaemia (MDS/AML). With the introduction of the ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) regimen...